116 related articles for article (PubMed ID: 22440858)
1. Noncovalent inhibition of 20S proteasome by pegylated dimerized inhibitors.
Maréchal X; Pujol A; Richy N; Genin E; Basse N; Reboud-Ravaux M; Vidal J
Eur J Med Chem; 2012 Jun; 52():322-7. PubMed ID: 22440858
[TBL] [Abstract][Full Text] [Related]
2. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome.
Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M
J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790
[TBL] [Abstract][Full Text] [Related]
3. 20S proteasome inhibition: designing noncovalent linear peptide mimics of the natural product TMC-95A.
Groll M; Gallastegui N; Maréchal X; Le Ravalec V; Basse N; Richy N; Genin E; Huber R; Moroder L; Vidal J; Reboud-Ravaux M
ChemMedChem; 2010 Oct; 5(10):1701-5. PubMed ID: 20715286
[No Abstract] [Full Text] [Related]
4. TMC-95A analogues with endocyclic biphenyl ether group as proteasome inhibitors.
Kaiser M; Milbradt AG; Siciliano C; Assfalg-Machleidt I; Machleidt W; Groll M; Renner C; Moroder L
Chem Biodivers; 2004 Jan; 1(1):161-73. PubMed ID: 17191784
[TBL] [Abstract][Full Text] [Related]
5. TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome.
Groll M; Götz M; Kaiser M; Weyher E; Moroder L
Chem Biol; 2006 Jun; 13(6):607-14. PubMed ID: 16793518
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitors: Dozens of molecules and still counting.
de Bettignies G; Coux O
Biochimie; 2010 Nov; 92(11):1530-45. PubMed ID: 20615448
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors.
Zhu Y; Yao S; Xu B; Ge Z; Cui J; Cheng T; Li R
Bioorg Med Chem; 2009 Oct; 17(19):6851-61. PubMed ID: 19747832
[TBL] [Abstract][Full Text] [Related]
8. Vinyl ester-based cyclic peptide proteasome inhibitors.
Baldisserotto A; Marastoni M; Fiorini S; Pretto L; Ferretti V; Gavioli R; Tomatis R
Bioorg Med Chem Lett; 2008 Mar; 18(6):1849-54. PubMed ID: 18294845
[TBL] [Abstract][Full Text] [Related]
9. Novel fluorinated pseudopeptides as proteasome inhibitors.
Formicola L; Maréchal X; Basse N; Bouvier-Durand M; Bonnet-Delpon D; Milcent T; Reboud-Ravaux M; Ongeri S
Bioorg Med Chem Lett; 2009 Jan; 19(1):83-6. PubMed ID: 19041239
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome.
Xu K; Wang K; Yang Y; Yan DA; Huang L; Chen CH; Xiao Z
Eur J Med Chem; 2015 Jun; 98():61-8. PubMed ID: 26005024
[TBL] [Abstract][Full Text] [Related]
11. Binding mode of TMC-95A analogues to eukaryotic 20S proteasome.
Kaiser M; Groll M; Siciliano C; Assfalg-Machleidt I; Weyher E; Kohno J; Milbradt AG; Renner C; Huber R; Moroder L
Chembiochem; 2004 Sep; 5(9):1256-66. PubMed ID: 15368577
[TBL] [Abstract][Full Text] [Related]
12. Development of peptidomimetic boronates as proteasome inhibitors.
Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M
Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651
[TBL] [Abstract][Full Text] [Related]
13. Retro hydrazino-azapeptoids as peptidomimetics of proteasome inhibitors.
Aubin S; Martin B; Delcros JG; Arlot-Bonnemains Y; Baudy-Floc'h M
J Med Chem; 2005 Jan; 48(1):330-4. PubMed ID: 15634028
[TBL] [Abstract][Full Text] [Related]
14. Novel organic proteasome inhibitors identified by virtual and in vitro screening.
Basse N; Montes M; Maréchal X; Qin L; Bouvier-Durand M; Genin E; Vidal J; Villoutreix BO; Reboud-Ravaux M
J Med Chem; 2010 Jan; 53(1):509-13. PubMed ID: 19919035
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the ubiquitin-proteasome system by natural products for cancer therapy.
Tsukamoto S; Yokosawa H
Planta Med; 2010 Aug; 76(11):1064-74. PubMed ID: 20186654
[TBL] [Abstract][Full Text] [Related]
16. The core structure of TMC-95A is a promising lead for reversible proteasome inhibition.
Kaiser M; Groll M; Renner C; Huber R; Moroder L
Angew Chem Int Ed Engl; 2002 Mar; 41(5):780-3. PubMed ID: 12491334
[No Abstract] [Full Text] [Related]
17. Linear TMC-95-based proteasome inhibitors.
Basse N; Piguel S; Papapostolou D; Ferrier-Berthelot A; Richy N; Pagano M; Sarthou P; Sobczak-Thépot J; Reboud-Ravaux M; Vidal J
J Med Chem; 2007 Jun; 50(12):2842-50. PubMed ID: 17511440
[TBL] [Abstract][Full Text] [Related]
18. The natural product hybrid of Syringolin A and Glidobactin A synergizes proteasome inhibition potency with subsite selectivity.
Clerc J; Li N; Krahn D; Groll M; Bachmann AS; Florea BI; Overkleeft HS; Kaiser M
Chem Commun (Camb); 2011 Jan; 47(1):385-7. PubMed ID: 20830349
[TBL] [Abstract][Full Text] [Related]
19. New cyclic peptide proteasome inhibitors.
Baldisserotto A; Marastoni M; Gavioli R; Tomatis R
Bioorg Med Chem Lett; 2009 Apr; 19(7):1966-9. PubMed ID: 19250821
[TBL] [Abstract][Full Text] [Related]
20. Stereocontrolled synthesis of the northern part of potent proteasome inhibitor TMC-95A.
Inoue M; Furuyama H; Sakazaki H; Hirama M
Org Lett; 2001 Sep; 3(18):2863-5. PubMed ID: 11529776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
